Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Matthew P. Cunningham

Responses of Human Colorectal Tumor Cells to Treatment With the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination With the EGFR Tyrosine Kinase Inhibitor Gefitinib

Cancer Research

Oncology

2006

English

Related publications

Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination With Chemotherapy

Clinical Cancer Research

Cancer Research

Oncology

2005

English

Combined Epidermal Growth Factor Receptor Targeting With the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting

Clinical Cancer Research

Cancer Research

Oncology

2004

English

Responses of Cancer Cells With Wild-Type or Tyrosine Kinase Domain-Mutated Epidermal Growth Factor Receptor (EGFR) to EGFR-targeted Therapy Are Linked to Downregulation of Hypoxia-Inducible Factor-1α

English

Comparison of the Characteristics of Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR‑tyrosine Kinase Inhibitor Treatment in Patients With Non‑small Cell Lung Cancer From Different Ethnic Groups

Experimental and Therapeutic Medicine

English

Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Clinical Cancer Research

Cancer Research

Oncology

2004

English

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Molecular and Cellular Proteomics

English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy

Oncology

Pharmacology

2019

English

Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (Gefitinib) Augments Pneumonitis, but Attenuates Lung Fibrosis in Response to Radiation Injury in Rats

Journal of Medical Investigation

English

Does the Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Differ According to the Type of EGFR Mutation in Non-Small Cell Lung Cancer?

Korean Journal of Internal Medicine

Internal Medicine

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Matthew P. Cunningham

Responses of Human Colorectal Tumor Cells to Treatment With the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination With the EGFR Tyrosine Kinase Inhibitor Gefitinib

Related publications

Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination With Chemotherapy

Combined Epidermal Growth Factor Receptor Targeting With the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting

Responses of Cancer Cells With Wild-Type or Tyrosine Kinase Domain-Mutated Epidermal Growth Factor Receptor (EGFR) to EGFR-targeted Therapy Are Linked to Downregulation of Hypoxia-Inducible Factor-1α

Comparison of the Characteristics of Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR‑tyrosine Kinase Inhibitor Treatment in Patients With Non‑small Cell Lung Cancer From Different Ethnic Groups

Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (Gefitinib) Augments Pneumonitis, but Attenuates Lung Fibrosis in Response to Radiation Injury in Rats

Does the Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Differ According to the Type of EGFR Mutation in Non-Small Cell Lung Cancer?